ArticleEinstein (Sao Paulo, Brazil)2019

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.

Pedro Nazareth Aguiar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.